Trial · NCT00439270
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
NCT00439270, Phase 1, Phase 2, Completed, Bristol-Myers Squibb; results first posted 2013-11-27
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer. Trials, record NCT00439270. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00439270
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
- NCT number
- NCT00439270
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 49 participants, actual
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Dasatinib, Docetaxel
- First posted
- 2007-02-23
- Last updated
- 2014-03-28
- Results first posted
- 2013-11-27
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel | From Day 3 of first 21-day cycle to Cycle 2 , Day 21 (or Study Day 42) | MTD was defined by dose-limiting toxicity (DLT) criteria. DLT was defined as grade 4 neutropenia causing treatment interruption for \>14 days, febrile neutropenia, grade 4 thrombocytopenia, grade 3 thrombocytopenia with a bleeding episode requiring platelet transfusion, nausea and/or vomiting despite medical intervention/prophylaxis causing treatment interruption for \>14 days, grade 3-4 asthenia/fatigue, any other grade \>=3 nonhematologic toxicity except alopecia or transient arthralgia/myalgia (unless unresponsive to intervention), or interruption of study drug for \>14 days due to toxicity. When defined, the MTD would serve as recommended Phase 2 dose of each drug in the combination of oral dasatinib and intravenous docetaxel. |
| Primary | Recommended Phase 2 Dose of Dasatinib Administered With Docetaxel, 75 mg/m^2 | From Day 3 of first 21-day cycle to Cycle 2 , Day 21 (or Study Day 42) | Because no dose-limiting toxicities occurred, the recommended dose of dasatinib used in Phase 2 was based on findings from ongoing studies in chronic myelogenous leukemia and experience from the previous Phase 2 study of single-agent dasatinib in chronic refractory prostate cancer. The recommended Phase 2 dose of docetaxel (75 mg/m\^2) was based on the docetaxel package insert. |
| Secondary | Percentage of Participants With a Prostate Specific Antigen (PSA) Response | At pretreatment visit, and on Day 1 of Cycles 2 through 12, then every other cycle, where investigator deems appropriate, and at end of treatment (up to 51.6 months) | PSA response rate is defined as a decrease of \>=50% in PSA levels from baseline, sustained for at least 6 weeks and confirmed by at least 2 measurements |
| Secondary | Duration of Prostate Specific Antigen (PSA) Response | At pretreatment visit, and on Day 1 of Cycles 2 through 12, then every other cycle, where investigator deems appropriate, and at end of treatment | Duration of response is computed for participants with confirmed PSA response. It is measured in months from the time of the first of 2 consecutive measurements meeting the criteria for confirmed PSA response to the date of the first of 3 consecutive measurements that confirm PSA progression, the date of disease progression, or the date of death. Participants who neither progressed (PSA or disease) nor died were censored on the date of their last PSA assessment. PSA response is defined as a decrease of \>=50% in PSA levels from baseline, sustained for at least 6 weeks and confirmed by at least 2 measurements. PSA progression is defined as 3 consecutive increases in PSA from baseline or nadir, each measurement at least 1 week apart. The final confirming PSA measurement had to be ≥5ng/mL higher than baseline or nadir and also represent at least a 50% increase from baseline or nadir (ie, the value is ≥1.5\*baseline or nadir PSA). |
| Secondary | Number of Months of Progression-free Survival (PFS) | Patients with an event: time from first dose to disease progression or death, whichever occurs first. Patients without an event: time to last on-study PSA measurement, tumor assessment, or radionuclide bone scan assessment, whichever occurs last | PFS defined as time in months from the first dosing date to the date of disease progression or the date of death. Patients who neither progressed nor died were censored on the date of their last on-study prostate specific antigen (PSA) measurement, tumor assessment, or radionuclide bone scan assessment (whichever occurred last). Disease progression defined as either of the following: progression on radionuclide bone scan, death, or at least 2 of the following: tumor progression, as defined by modified Response Evaluation Criteria in Solid Tumors; PSA progression; or investigator-defined clinical progression based on physical examination, history, symptoms, and performance status. |
| Secondary | Percentage of Participants With an Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Pretreatment visit then every 6 weeks thereafter (up to 51.6 months) | Objective response rate is defined as the percentage of participants who have achieved best responses of confirmed Complete Response (CR) or Partial Response (PR) where confirmed requires repeat evaluations for a minimum of 4 weeks after the criteria for response are first met. RECIST: CR=disappearance of clinical and radiologic evidence of target lesions; PR=a 30% or greater decrease in the sum of the longest diameter (LD) of all lesions in reference to the baseline sum LD. |
| Secondary | Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Pretreatment visit then every 6 weeks thereafter (up to 51.6 months) | RECIST for target lesions: Complete Response (CR)=disappearance of clinical and radiologic evidence of target lesions. Partial Response (PR)=a 30% or greater decrease in the sum of the longest diameter (LD) of all lesions in reference to the baseline sum LD. Stable disease (SD)=neither sufficient increase to qualify for Progressive Disease (PD) nor sufficient shrinkage to qualify for PR. PD=a 20% or greater increase in the sum of LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline; unequivocal progression of nonmeasurable disease/lesions as evaluated by CT scan or MRI (not as evaluated by radionuclide bone scan) and/or new lesions are present. To qualify as SD, patients had to exhibit SD for a minimum of 18 weeks. Those with evaluations noted as SD prior to 18 weeks and discontinued were reported as no change. |
| Secondary | Number of Participants by Best On-study Bone Scan Assessment From Baseline | From Day 1 of therapy to last bone scan assessment (up to 51.6 months) | Stable=no new lesions appeared at any 6-week assessment or new pain was not developed in an area that was previously visualized for a minimum of 18 weeks; no change=stable disease prior to 18 weeks and then discontinued treatment; progression=2 or more new areas of focal uptake or new adverse clinical symptoms in an area previously visualized; improved=disappearance of at least 1 lesion, no new lesions appearing since the most recent prior assessment, and new pain not developing in an area that was previously visualized. |
| Secondary | Percentage of Participants With Improvement on Bone Scan | From Day 1 of therapy to last bone scan assessment (up to 51.6 months) | Improvement=disappearance of at least 1 lesion, no new lesions appearing since the most recent prior assessment, and new pain not developing in an area that was previously visualized |
| Secondary | Baseline Scores and Changes in Pain Intensity From Baseline on the Brief Pain Inventory Short Form (BPI-sf) Scores Through Cycle 6 | At pretreatment visit and on Day 1 of Cycles 2 through 6, then Day 1 of every other cycle, at end of treatment, and at follow-up visit | The BPI-sf assessed intensity of pain in the last 24 hours as well as impact of pain on daily functions. Patients rated the severity of their pain at its worst, least, and average in the last 24 hours using an 11-point rating scale with endpoints of no pain (0 points) and pain as bad as you can imagine (11 points). They were asked to rate their present pain and pain at the time they completed the BPI-sf. Using an 11-point rating scale with endpoints of does not interfere (0 points) and completely interferes (11 points), the BPI-sf similarly assessed to what extent pain interfered with mood, walking, general activity, work, relations with others, sleep, and enjoyment of life. The BPI-sf also asked patients to mark the location of their pain on a body drawing and included other questions about pain treatment and the extent of pain relief. The BPI-sf was collected in the Phase 2 portion of the study only. For on-treatment visits, the BPI-sf was completed prior to the docetaxel infusion. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Percentage of Participants With a Prostate Specific Antigen (PSA) Response | At pretreatment visit, and on Day 1 of Cycles 2 through 12, then every other cycle, where investigator deems appropriate, and at end of treatment (up to 51.6 months) | All patients who received dasatinib, 100 mg + docetaxel, 75 mg/m\^2 | Percentage of participants | NUMBER |
| PRIMARY | Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel | From Day 3 of first 21-day cycle to Cycle 2 , Day 21 (or Study Day 42) | All patients who received at least 1 dose of dasatinib in Phase 1 | mg | NUMBER |
| SECONDARY | Duration of Prostate Specific Antigen (PSA) Response | At pretreatment visit, and on Day 1 of Cycles 2 through 12, then every other cycle, where investigator deems appropriate, and at end of treatment | All participants who received dasatinib, 100 mg + docetaxel, 75 mg/m\^2 and who had a PSA response | Months | MEDIAN |
| SECONDARY | Number of Months of Progression-free Survival (PFS) | Patients with an event: time from first dose to disease progression or death, whichever occurs first. Patients without an event: time to last on-study PSA measurement, tumor assessment, or radionuclide bone scan assessment, whichever occurs last | All patients who received dasatinib, 100 mg + docetaxel, 75 mg/m\^2 | Months | MEDIAN |
| SECONDARY | Percentage of Participants With an Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Pretreatment visit then every 6 weeks thereafter (up to 51.6 months) | All patients who received dasatinib, 100 mg + docetaxel, 75 mg/m\^2 | Percentage of participants | NUMBER |
| SECONDARY | Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Pretreatment visit then every 6 weeks thereafter (up to 51.6 months) | All patients who received dasatinib, 100 mg + docetaxel, 75 mg/m\^2 | Participants | NUMBER |
| PRIMARY | Recommended Phase 2 Dose of Dasatinib Administered With Docetaxel, 75 mg/m^2 | From Day 3 of first 21-day cycle to Cycle 2 , Day 21 (or Study Day 42) | All patients who received at least 1 dose of dasatinib in Phase 1 | mg | NUMBER |
| SECONDARY | Number of Participants by Best On-study Bone Scan Assessment From Baseline | From Day 1 of therapy to last bone scan assessment (up to 51.6 months) | All patients who received dasatinib, 100 mg + docetaxel, 75 mg/m\^2 | Participants | NUMBER |
| SECONDARY | Percentage of Participants With Improvement on Bone Scan | From Day 1 of therapy to last bone scan assessment (up to 51.6 months) | All patients who received dasatinib, 100 mg + docetaxel, 75 mg/m\^2 | Percentage of participants | NUMBER |
| SECONDARY | Baseline Scores and Changes in Pain Intensity From Baseline on the Brief Pain Inventory Short Form (BPI-sf) Scores Through Cycle 6 | At pretreatment visit and on Day 1 of Cycles 2 through 6, then Day 1 of every other cycle, at end of treatment, and at follow-up visit | All patients who received dasatinib, 100 mg + docetaxel, 75 mg/m\^2, in the Phase 2 portion of the study and completed the BPI-sf at baseline. n=evaluable participants in that cycle. | Units on a scale | MEDIAN |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 outcomesResults by group151
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With a Prostate Specific Antigen (PSA) Response | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 64.7 | 95% Confidence Interval 46.49 to 80.25 | Percentage of participants | |
| Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel | All Treated (Phase 1) | NA | mg | ||
| Duration of Prostate Specific Antigen (PSA) Response | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 9.5 | 95% Confidence Interval 7.1 to 25.2 | Months | |
| Number of Months of Progression-free Survival (PFS) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 11.5 | 95% Confidence Interval 8.8 to 18.9 | Months | |
| Percentage of Participants With an Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 44.1 | 95% Confidence Interval 27.19 to 62.11 | Percentage of participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Complete response | 0 | Participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Partial response | 15 | Participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Stable disease | 1 | Participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | No change | 3 | Participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Progressive disease | 2 | Participants |
1 to 10 of 151Source ClinicalTrials.gov
See all 151 results by groupParticipant flow30
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase 1 (18.1 Months) | STARTED | Dasatinib, 50 mg + Docetaxel, 60 mg/m^2 | 3 | |
| Phase 1 (18.1 Months) | STARTED | Dasatinib, 50 mg + Docetaxel, 75 mg/m^2 | 3 | |
| Phase 1 (18.1 Months) | STARTED | Dasatinib, 70 mg + Docetaxel, 75 mg/m^2 | 3 | |
| Phase 1 (18.1 Months) | STARTED | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 4 | |
| Phase 1 (18.1 Months) | STARTED | Dasatinib, 120 mg + Docetaxel, 75 mg/m^2 | 3 | |
| Phase 1 (18.1 Months) | COMPLETED | Dasatinib, 50 mg + Docetaxel, 60 mg/m^2 | 0 | |
| Phase 1 (18.1 Months) | COMPLETED | Dasatinib, 50 mg + Docetaxel, 75 mg/m^2 | 0 | |
| Phase 1 (18.1 Months) | COMPLETED | Dasatinib, 70 mg + Docetaxel, 75 mg/m^2 | 0 | |
| Phase 1 (18.1 Months) | COMPLETED | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 4 | |
| Phase 1 (18.1 Months) | COMPLETED | Dasatinib, 120 mg + Docetaxel, 75 mg/m^2 | 0 |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 participant flowAdverse events755
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Back pain | Musculoskeletal and connective tissue disorders | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 5 | 34 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Dasatinib, 120 mg + Docetaxel, 75 mg/m^2 | 2 | 3 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Dasatinib, 50 mg + Docetaxel, 60 mg/m^2 | 0 | 3 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Dasatinib, 50 mg + Docetaxel, 75 mg/m^2 | 0 | 3 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Dasatinib, 70 mg + Docetaxel, 75 mg/m^2 | 0 | 3 | |
| other | Blood lactate dehydrogenase increased | Investigations | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 1 | 34 | |
| other | Blood lactate dehydrogenase increased | Investigations | Dasatinib, 120 mg + Docetaxel, 75 mg/m^2 | 1 | 3 | |
| other | Blood lactate dehydrogenase increased | Investigations | Dasatinib, 50 mg + Docetaxel, 60 mg/m^2 | 0 | 3 | |
| other | Blood lactate dehydrogenase increased | Investigations | Dasatinib, 50 mg + Docetaxel, 75 mg/m^2 | 0 | 3 | |
| other | Blood lactate dehydrogenase increased | Investigations | Dasatinib, 70 mg + Docetaxel, 75 mg/m^2 | 0 | 3 |
1 to 10 of 755Source ClinicalTrials.gov
See all 755 adverse eventsAdverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | ||
| Total, all-cause mortality | Dasatinib, 120 mg + Docetaxel, 75 mg/m^2 | ||
| Total, all-cause mortality | Dasatinib, 50 mg + Docetaxel, 60 mg/m^2 | ||
| Total, all-cause mortality | Dasatinib, 50 mg + Docetaxel, 75 mg/m^2 | ||
| Total, all-cause mortality | Dasatinib, 70 mg + Docetaxel, 75 mg/m^2 | ||
| Total, other adverse events | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 34 | 34 |
| Total, other adverse events | Dasatinib, 120 mg + Docetaxel, 75 mg/m^2 | 3 | 3 |
| Total, other adverse events | Dasatinib, 50 mg + Docetaxel, 60 mg/m^2 | 3 | 3 |
| Total, other adverse events | Dasatinib, 50 mg + Docetaxel, 75 mg/m^2 | 3 | 3 |
| Total, other adverse events | Dasatinib, 70 mg + Docetaxel, 75 mg/m^2 | 3 | 3 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21976132 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00439270
GET https://conductscience.org/api/trials/v1/NCT00439270/results?page=2